Clinical Validation of SMARTDIAGO for Remote Functional Assessment of Musculoskeletal Conditions
Key facts
- Where
- Santiago, ChileSee the 2 sites
Where in Chile
- Hospital Clínico Universidad de ChileSantiago, ChileContact: Maximiliano Barahona, MDNo longer taking part
- Hospital San JoséSantiago, ChileContact: Mauricio CerdaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Chile
- Trial code
- NCT07880210
- Record updated
- 19 October 2026
- Original description
Clinical validation of SMARTDIAGO, an artificial intelligence-based system for remote functional assessment of patients with musculoskeletal disorders and functional frailty. The study will compare remote assessments performed using SMARTDIAGO with standardized in-person clinical evaluations to determine diagnostic accuracy, agreement, and operational feasibility.Read full original descriptionShow less
Clinical Validation of the SMARTDIAGO System: A Remote Diagnostic Tool for Musculoskeletal Disorders Using Artificial Intelligence and Functional Video Analysis
Clinical validation of SMARTDIAGO, an artificial intelligence-based system for remote functional assessment of patients with musculoskeletal disorders and functional frailty. The study will compare remote assessments performed using SMARTDIAGO with standardized in-person clinical evaluations to determine diagnostic accuracy, agreement, and operational feasibility.
Inclusion: Age 55 years or older; Referral from primary care for knee, hip, shoulder, or spine disorders, or age 60 years or older with functional frailty; Access to a smartphone or computer with a camera; Ability to perform simple functional movements, including sitting down and standing up from a chair.
Exclusion: Recent surgery within the previous three months; Uncontrolled neurological or cardiopulmonary conditions; Mild cognitive impairment with insufficient social support, or moderate-to-severe cognitive impairment; Severe pain at rest (greater than 7/10); Pregnancy; Simultaneous participation in another clinical research study.